SGC707
Based on 12 publication(s) in Google Scholar
SGC707, a chemical probe, is a potent, selective, and non-competitive PRMT3 (protein arginine methyltransferase 3) inhibitor (IC50=31 nM, Kd=53 nM).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.99%
- No. CAS: 1687736-54-4
- Fòrmula: C16H18N4O2
- Peso molecular:298.34
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Reprogramming Compound Library
HY-L039
-
Chemical Probe Library
HY-L063
-
Anti-Blood Cancer Compound Library
HY-L079
-
Transcription Factor-Targeted Library
HY-L090
-
Targeted Diversity Library
HY-L099
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Methylation Compound Library
HY-L203
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) SGC707
More- Cancer Res. 2025 Oct 23. [Abstract]
- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Adv Sci (Weinh). 2023 Dec;10(36):e2303812. [Abstract]
- Chem Eng J. 2026 Feb 14.
- Cell Death Dis. 2025 Mar 6;16(1):158. [Abstract]
- Cell Death Dis. 2021 Nov 9;12(11):1066. [Abstract]
- Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966. [Abstract]
- Clin Transl Med. 2022 Jan;12(1):e686. [Abstract]
- Poult Sci. 2024 Jun 17;103(9):103989. [Abstract]
- FASEB J. 2020 Aug;34(8):10212-10227. [Abstract]
- Mol Carcinog. 2023 Aug;62(8):1119-1135. [Abstract]
- University of Munich. 2022 Oct.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
In Vivo Efficacy Study
-
WB
-
WB
Ver todos los productos específicos de isoformas Histone Methyltransferase
More
Actividad biológica
|
PRMT3 31 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | EC50 |
2 μM
Compound: 4; SGC707
|
Binding affinity to beta galactosidase fused human PRMT3 (211 to 531 residues) expressed in human A549 cells after 6 hrs by InCELL hunter assay
Binding affinity to beta galactosidase fused human PRMT3 (211 to 531 residues) expressed in human A549 cells after 6 hrs by InCELL hunter assay
|
[PMID: 29244490] |
| HEK293 | EC50 |
1.8 μM
Compound: 4; SGC707
|
Binding affinity to beta galactosidase fused human PRMT3 (211 to 531 residues) expressed in human HEK293 cells after 6 hrs by InCELL hunter assay
Binding affinity to beta galactosidase fused human PRMT3 (211 to 531 residues) expressed in human HEK293 cells after 6 hrs by InCELL hunter assay
|
[PMID: 29244490] |
| HEK293 | IC50 |
225 nM
Compound: 4; SGC707
|
Inhibition of FLAG-tagged wild type human PRMT3 expressed in HEK293 cells assessed as reduction in endogenous H4R3me2a level using GFP-tagged histone H4 as substrate after 24 hrs by Western blot analysis
Inhibition of FLAG-tagged wild type human PRMT3 expressed in HEK293 cells assessed as reduction in endogenous H4R3me2a level using GFP-tagged histone H4 as substrate after 24 hrs by Western blot analysis
|
[PMID: 29244490] |
| HEK293 | IC50 |
91 nM
Compound: 4; SGC707
|
Inhibition of FLAG-tagged wild type human PRMT3 expressed in HEK293 cells assessed as decrease in exogenous H4R3 dimethylation level using GFP-tagged histone H4 as substrate after 24 hrs by Western blot analysis
Inhibition of FLAG-tagged wild type human PRMT3 expressed in HEK293 cells assessed as decrease in exogenous H4R3 dimethylation level using GFP-tagged histone H4 as substrate after 24 hrs by Western blot analysis
|
[PMID: 29244490] |
SGC707 (0-10 μM; 6 h) binds to PRMT3 in both HEK293 and A549 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HEK293 and A549 cells
-
Concentration:0-10 μM
-
Incubation Time:6 hours
-
Result:Stabilized PRMT3 in both HEK293 and A549 cells with EC50 values of 1.3 μM and 1.6 μM, respectively.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Western-type diet-fed LDL (lipoprotein) receptor knockout mice[2]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; 10 mg/kg; 3 times per week; 3 weeks
-
Result:Exhibited 50% lower liver triglyceride stores as well as 32% lower plasma triglyceride levels.
Chemical Information
-
No. CAS 1687736-54-4
-
Appearance Solid
-
Peso molecular 298.34
-
Fòrmula C16H18N4O2
-
Color Light yellow to yellow
-
SMILES
O=C(NCC(N1CCCC1)=O)NC2=CC=C3C=NC=CC3=C2
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Cancer Res
PRMT3 Drives IDO1-Dependent Radioresistance and Immunosuppression by Promoting Kynurenine Metabolism in Non-Small Cell Lung Cancer. [Abstract]2025 Oct 23. PMID: 41129671
SGC707 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Oct 23. [Abstract]
PDX tumors were treated with the PRMT3 inhibitor SGC707 (10 mg/kg, every 2 days via intraperitoneal injection) and/or radiotherapy (8 Gy/day, three consecutive days). D, day; PDO, patient-derived tumor organoid.
SGC707 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Oct 23. [Abstract]
PDX tumors were treated with the PRMT3 inhibitor SGC707 (10 mg/kg, every 2 days via intraperitoneal injection) and/or radiotherapy (8 Gy/day, three consecutive days). Tumor growth curve was plotted (n = 3 mice per group).
SGC707 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Oct 23. [Abstract]
Corresponding patient-derived tumor organoids were treated with SGC707 (10 μmol/L) and/or radiotherapy (8 Gy, once).
SGC707 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Oct 23. [Abstract]
The PRMT3 inhibitor SGC707 rescued the effects of PRMT3 overexpression on TFAP2A half-life.
SGC707 purchased from MedChemExpress. Usage Cited in: Cancer Res. 2025 Oct 23. [Abstract]
The PRMT3 inhibitor SGC707 rescued the effects of PRMT3 overexpression on nuclear localization.
-
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Adv Sci (Weinh)
PRMT3-Mediated Arginine Methylation of METTL14 Promotes Malignant Progression and Treatment Resistance in Endometrial Carcinoma. [Abstract]2023 Dec;10(36):e2303812. PMID: 37973560 -
-
Cell Death Dis
PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma. [Abstract]2025 Mar 6;16(1):158. PMID: 40050608 -
Cell Death Dis
2021 Nov 9;12(11):1066. PMID: 34753906 -
Proc Natl Acad Sci U S A
2019 Feb 19;116(8):2961-2966. PMID: 30718431 -
Clin Transl Med
Protein arginine methyltransferase 3 promotes glycolysis and hepatocellular carcinoma growth by enhancing arginine methylation of lactate dehydrogenase A. [Abstract]2022 Jan;12(1):e686. PMID: 35090076 -
Poult Sci
2024 Jun 17;103(9):103989. PMID: 38981362 -
FASEB J
2020 Aug;34(8):10212-10227. PMID: 32643209
SGC707 purchased from MedChemExpress. Usage Cited in: FASEB J. 2020 Aug;34(8):10212-10227. [Abstract]
The effect of SGC707 on the key antiviral gene expression after SVCV and GCRV infection in ZFL cells is examined by qRT‐PCR assays. The addition of SGC707 enhances poly (I:C), and SVCV‐ induced IFN activation in EPC cells. SGC707 also enhances the antiviral gene expression by SVCV infection or GCRV infection.
-
Mol Carcinog
PRMT1 inhibition promotes ferroptosis sensitivity via ACSL1 upregulation in acute myeloid leukemia. [Abstract]2023 Aug;62(8):1119-1135. PMID: 37144835 -
Solvente y solubilidad
DMSO : ≥ 100 mg/mL (335.19 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 3 mg/mL (10.06 mM); Clear solution
This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 3 mg/mL (10.06 mM); Clear solution
This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Kaniskan HÜ, et al. A potent, selective and cell-active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3). Angew Chem Int Ed Engl. 2015 Apr 20;54(17):5166-70. [Content Brief]
[2]. de Jong LM, et al. PRMT3 inhibitor SGC707 reduces triglyceride levels and induces pruritus in Western-type diet-fed LDL receptor knockout mice. Sci Rep. 2022 Jan 10;12(1):483. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.3519 mL | 16.7594 mL | 33.5188 mL | 83.7970 mL |
| 5 mM | 0.6704 mL | 3.3519 mL | 6.7038 mL | 16.7594 mL | |
| 10 mM | 0.3352 mL | 1.6759 mL | 3.3519 mL | 8.3797 mL | |
| 15 mM | 0.2235 mL | 1.1173 mL | 2.2346 mL | 5.5865 mL | |
| 20 mM | 0.1676 mL | 0.8380 mL | 1.6759 mL | 4.1899 mL | |
| 25 mM | 0.1341 mL | 0.6704 mL | 1.3408 mL | 3.3519 mL | |
| 30 mM | 0.1117 mL | 0.5586 mL | 1.1173 mL | 2.7932 mL | |
| 40 mM | 0.0838 mL | 0.4190 mL | 0.8380 mL | 2.0949 mL | |
| 50 mM | 0.0670 mL | 0.3352 mL | 0.6704 mL | 1.6759 mL | |
| 60 mM | 0.0559 mL | 0.2793 mL | 0.5586 mL | 1.3966 mL | |
| 80 mM | 0.0419 mL | 0.2095 mL | 0.4190 mL | 1.0475 mL | |
| 100 mM | 0.0335 mL | 0.1676 mL | 0.3352 mL | 0.8380 mL |
SGC707 Related Classifications
HY-19715 Related Classifications
Powered by Bioz